Trials / Unknown
UnknownNCT03276910
Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Association Athletes For Transparency · Academic / Other
- Sex
- Male
- Age
- 18 Years – 49 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this research is to demonstrate the possible use of erythroferrone (ERFE) as a potential marker of recombinant human erythropoietin (rHuEpo) use to be included in the Athlete Biological Passport (PBA) developed by the World Anti-Doping Agency (WADA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPREX | 6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use |
| DRUG | sodium chloride AGUETTANT 0.9% | 6 injections at 1ml in subcutaneous use |
Timeline
- Start date
- 2017-09-08
- Primary completion
- 2017-12-22
- Completion
- 2018-06-01
- First posted
- 2017-09-08
- Last updated
- 2017-09-08
Source: ClinicalTrials.gov record NCT03276910. Inclusion in this directory is not an endorsement.